DXCM vs. GKOS: DexCom vs. Glaukos Stock Comparison

Company Profile

DexCom (DXCM) and Glaukos (GKOS) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

DexCom (DXCM) has an aggressive beta of 1.43, indicating higher sensitivity to broad-market moves, while Glaukos (GKOS) is defensive at 0.68 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Glaukos (GKOS) reports a negative ROE of -22.84%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile DexCom (DXCM) reports 37.67%, ranking against industry peers normally.

Glaukos (GKOS) reports a negative net margin of -24.60%, usually indicating a net loss over the period. Meanwhile DexCom (DXCM) reports 19.42%, ranking against industry peers normally.

DexCom (DXCM) at 24.34% operates in the top operating margin quartile, ahead of Glaukos (GKOS) at 0.39%, which runs around its industry’s norm.

Profitability Metrics

Growth

Glaukos (GKOS) at 32.33% sits in the top revenue growth quartile, while DexCom (DXCM) at 15.60% is closer to the peer norm — faster top-line expansion for GKOS.

Only one side can be read here: DexCom (DXCM) reports EPS growth of 47.18%, ranked against its industry; Glaukos (GKOS) has no EPS growth figure this period.

Growth Metrics

Financial Strength

DexCom (DXCM) at 1.74 keeps current ratio within its industry’s typical mid-range, while Glaukos (GKOS) at 4.57 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Glaukos (GKOS) at 0.15 keeps leverage in the lower industry quartile, while DexCom (DXCM) at 0.55 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither DexCom (DXCM) nor Glaukos (GKOS) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither DexCom (DXCM) nor Glaukos (GKOS) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: DexCom (DXCM) trades at 31.26 times trailing earnings, ranked against its peers, while Glaukos (GKOS) has no P/E ratio this period.

Both look expensive on sales: DexCom (DXCM) at 5.80 sits in the upper P/S ratio quartile, and Glaukos (GKOS) at 19.24 prices even higher, above its industry range.

Both look rich against book: DexCom (DXCM) at 11.68 sits in the upper P/B ratio quartile, and Glaukos (GKOS) at 18.51 prices even higher, above its industry range.

Valuation Metrics